Clinical Trials · NCT07165886
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
- Phase
- Phase 2/Phase 3
- Recruitment status
- Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrollment
- 298
- Start date
- Aug 2025
- Locations
- 1 site, China
- Primary endpoint
- Phase II: Incidences of Adeverse Events (AEs)